Description
NGS: investing in deeper evaluation and optimised therapeutic decisions in myeloid neoplasms
Article: NGS: investing in deeper evaluation and optimised therapeutic decisions in myeloid neoplasms
€3.03
Related products
-
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in gynaecological cancers
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart
